AR130954A1 - Composiciones de anticuerpo anti-ctla y métodos relacionados - Google Patents
Composiciones de anticuerpo anti-ctla y métodos relacionadosInfo
- Publication number
- AR130954A1 AR130954A1 ARP230102949A ARP230102949A AR130954A1 AR 130954 A1 AR130954 A1 AR 130954A1 AR P230102949 A ARP230102949 A AR P230102949A AR P230102949 A ARP230102949 A AR P230102949A AR 130954 A1 AR130954 A1 AR 130954A1
- Authority
- AR
- Argentina
- Prior art keywords
- ctla
- seq
- amino acid
- acid sequence
- composition according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación proporciona composiciones que comprenden anticuerpos anti-CTLA-4 y métodos relacionados para tratar el cáncer y otros trastornos que responden al antagonismo anti-CTLA-4. Reivindicación 1: Una composición que comprende un anticuerpo anti-CTLA, en donde el anticuerpo anti-CTLA comprende un dominio variable de cadena ligera que comprende un CDRL1 que tiene la secuencia de aminoácidos de SEQ ID Nº 1, una CDRL2 que tiene la secuencia de aminoácidos de la SEQ ID Nº 2, y una CDRL3 que tiene la secuencia de aminoácidos de la SEQ ID Nº 3; y un dominio variable de la cadena pesada que comprende una CDRH1 que tiene la secuencia de aminoácidos de la SEQ ID Nº 4, una CDRH2 que tiene la secuencia de aminoácidos de la SEQ ID Nº 5, y una CDRH3 que tiene una secuencia de aminoácidos de la SEQ ID Nº 6; y una o más variantes desamidadas del anticuerpo anti-CTLA-4, en donde la composición comprende & Reivindicación 92: Una formulación que comprende la composición farmacéutica de conformidad con la reivindicación 85, en donde la formulación comprende: (a) aproximadamente 20 mg/mL de anticuerpo anti-CTLA-4; (b) aproximadamente 20 mM de tampón de histidina; (c) aproximadamente 222 mM de dihidrato de trehalosa; (d) aproximadamente 0.27 mM de dihidrato de edetato de sodio; y (e) aproximadamente 0.02% p/v de polisorbato 80, a un pH de aproximadamente 5.5. Reivindicación 93: Un dispositivo de inyección que comprende la composición de conformidad con cualquiera de las reivindicaciones 1 - 84, la composición farmacéutica de acuerdo con la reivindicación 85 o la formulación de acuerdo con cualquiera de las reivindicaciones 86 - 92. Reivindicación 94: Un medio de cultivo celular que comprende la composición de conformidad con cualquiera de las reivindicaciones 1 - 84. Reivindicación 95: Un eluato que comprende la composición de conformidad con cualquiera de las reivindicaciones 1 - 84.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263382398P | 2022-11-04 | 2022-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130954A1 true AR130954A1 (es) | 2025-02-05 |
Family
ID=88731370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102949A AR130954A1 (es) | 2022-11-04 | 2023-11-03 | Composiciones de anticuerpo anti-ctla y métodos relacionados |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250340643A1 (es) |
| EP (1) | EP4611898A1 (es) |
| JP (1) | JP2025536574A (es) |
| KR (1) | KR20250099736A (es) |
| CN (1) | CN120202024A (es) |
| AR (1) | AR130954A1 (es) |
| AU (1) | AU2023374714A1 (es) |
| IL (1) | IL320572A (es) |
| WO (1) | WO2024094831A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1865986B1 (en) * | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン,エルエルシー | 抗pd−l1および抗ctla−4抗体の共製剤を含む組成物 |
-
2023
- 2023-11-03 JP JP2025524800A patent/JP2025536574A/ja active Pending
- 2023-11-03 US US19/126,456 patent/US20250340643A1/en active Pending
- 2023-11-03 CN CN202380077036.7A patent/CN120202024A/zh active Pending
- 2023-11-03 EP EP23801711.5A patent/EP4611898A1/en active Pending
- 2023-11-03 KR KR1020257018375A patent/KR20250099736A/ko active Pending
- 2023-11-03 AR ARP230102949A patent/AR130954A1/es unknown
- 2023-11-03 WO PCT/EP2023/080627 patent/WO2024094831A1/en not_active Ceased
- 2023-11-03 AU AU2023374714A patent/AU2023374714A1/en active Pending
-
2025
- 2025-04-29 IL IL320572A patent/IL320572A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL320572A (en) | 2025-07-01 |
| KR20250099736A (ko) | 2025-07-02 |
| US20250340643A1 (en) | 2025-11-06 |
| EP4611898A1 (en) | 2025-09-10 |
| CN120202024A (zh) | 2025-06-24 |
| JP2025536574A (ja) | 2025-11-07 |
| WO2024094831A1 (en) | 2024-05-10 |
| AU2023374714A1 (en) | 2025-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016177A5 (es) | ||
| AR127344A2 (es) | Conjugados anticuerpo-fármaco que comprenden agonistas de sting | |
| JP2020518600A5 (es) | ||
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| JP2020518598A5 (es) | ||
| JP2023109942A5 (es) | ||
| PE20240814A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| UY39878A (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| PE20160994A1 (es) | Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento | |
| IL295383A (en) | High concentration anti-aß protofibril antibody formulations and methods of use thereof | |
| RU2020112280A (ru) | Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение | |
| AR115365A1 (es) | Formulaciones de anticuerpos anti-pd-l1 humanos | |
| PE20221281A1 (es) | Formulaciones de anticuerpos anti-pd-l1 | |
| PE20221865A1 (es) | Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| MX2022010751A (es) | Anticuerpo biespecifico. | |
| IL276911B1 (en) | Variants of the carboxylation rate of antibodies | |
| AR130144A1 (es) | Proteínas de unión a nkg2d, cd16 y ceacam5 | |
| AR123085A1 (es) | FORMULACIONES DE ANTICUERPO ANTI-INTEGRINA b7 Y DISPOSITIVOS | |
| AR130041A1 (es) | Formulaciones de anticuerpos anti-tl1a |